抗トロンビンIII検査市場：製品タイプ、技術、用途、エンドユーザー別-2025～2030年の世界予測

抗トロンビンIII検査市場は、2023年に9,143万米ドルと評価され、2024年には9,984万米ドルに達すると予測され、CAGR 9.39%で成長し、2030年には1億7,137万米ドルに達すると予測されています。

抗トロンビンIII検査は、血栓性疾患の診断と管理、抗凝固療法の有効性確保に重要な役割を果たすため、医療セグメントでは不可欠です。この検査の必要性は、血栓症のリスク上昇につながる抗トロンビンIIIの先天性または後天性欠損の検出に応用されることによってもたらされます。その用途は、病院の検査室、診断センター、研究機関などの医療環境にまたがり、主要なエンドユーザーとなっています。市場成長は、血栓塞栓性障害の発生率の上昇、診断技術の進歩、血液凝固障害を起こしやすい高齢者の増加などの影響を受けています。凝固障害に対する意識の高まりが需要をさらに増大させています。最近では、ポイントオブケア診断ツールや、精度と効率向上のための人工知能の統合を促進する技術の進歩から、潜在的なビジネス機会が生まれています。企業は研究提携に投資し、最先端技術で製品ポートフォリオを強化することで、こうした機会を活用することができます。しかし、市場成長は、厳しい規制要件、高い検査コスト、検査実施と結果の正確な解釈のための熟練した専門家の必要性などの課題に直面しています。こうした限界は、特に低所得地域における普及の妨げとなる可能性があります。イノベーションと調査は、非侵襲的検査法の強化、コスト削減、デジタル技術の活用に重点を置き、より容易なアクセスと合理化された診断を確保すべきです。個別化医療のアプローチを重視し、強固な予測モデルを開発することで、ビジネス成長の新たな道が開ける。この市場は本質的に協調的であり、病院、診断サービスプロバイダー、学術研究機関とのパートナーシップがイノベーションを推進する可能性があります。全体として、市場情勢はダイナミックであり、技術革新と戦略的市場関与の融合は、既存の課題にもかかわらず、大きな成長機会を提供することができます。

市場力学：急速に進化する抗トロンビンIII検査市場の主要市場洞察を公開

抗トロンビンIII検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域における様々なリスクを軽減することができ、また消費者行動や、それが製造コストや購買傾向に与える影響についてもより明確に理解することができます。

ポーターの5つの力：抗トロンビンIII検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、抗トロンビンIII検査市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗トロンビンIII検査市場における外部からの影響の把握

外部マクロ環境要因は、抗トロンビンIII検査市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗トロンビンIII検査市場における競合情勢の把握

抗トロンビンIII検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス抗トロンビンIII検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗トロンビンIII検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗トロンビンIII検査市場における成功への道筋を描く

抗トロンビンIII検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：現在の市場環境についての詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セクターにおける拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを調査します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行えるよう、重要な質問にも回答しています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • より良い周術期ケアのためにアンチトロンビンIIIモニタリングを必要とする外科手術の増加
    • 定期的な血栓症の予防が必要な高齢者の増加
    • 新興国における医療インフラの拡大
  • 抑制要因
    • 抗トロンビンIII検査の熟練した専門家と専門研究所の数が限られている
  • 機会
    • 心臓血管専門医療施設における抗トロンビンIII検査サービスの拡大
    • バイオテクノロジー企業とのコラボレーションによる新しい抗トロンビンIII検査方法論の革新
  • 課題
    • 規制遵守と厳格なガイドライン
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗トロンビンIII検査市場：製品タイプ別

• イントロダクション
• 心臓検査キット
• ELISA検査キット
• FIAテストキット

第7章 抗トロンビンIII検査市場：技術別

• イントロダクション
• 発色アッセイ
• 免疫測定

第8章 抗トロンビンIII検査市場：用途別

• イントロダクション
• 診断ラボ
  • 病院の検査室
  • 独立系診断ラボ
• ポイントオブケア検査
• 研究・学術機関
  • 臨床研究ユニット
  • 大学・短期大学

第9章 抗トロンビンIII検査市場：エンドユーザー別

• イントロダクション
• 外来手術センター
• 診断ラボ
• 病院
• 専門クリニック

第10章 南北アメリカの抗トロンビンIII検査市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の抗トロンビンIII検査市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの抗トロンビンIII検査市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Abbott Laboratories
• 2. Agilent Technologies
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories
• 5. bioMerieux
• 6. Chrono-log Corporation
• 7. Danaher Corporation
• 8. DiaSorin
• 9. Grifols
• 10. Immucor
• 11. Instrumentation Laboratory
• 12. Merck KGaA
• 13. PerkinElmer
• 14. Quidel Corporation
• 15. Roche Diagnostics
• 16. Sekisui Diagnostics
• 17. Siemens Healthineers
• 18. Sysmex Corporation
• 19. Thermo Fisher Scientific
• 20. Werfen

LIST OF FIGURES

• FIGURE 1. ANTI-THROMBIN III TESTING MARKET RESEARCH PROCESS
• FIGURE 2. ANTI-THROMBIN III TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ANTI-THROMBIN III TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ANTI-THROMBIN III TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-THROMBIN III TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-THROMBIN III TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY CARDIAC TEST KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY ELISA TEST KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY FIA TEST KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY CHROMOGENIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY INDEPENDENT DIAGNOSTICS LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY CLINICAL RESEARCH UNITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY UNIVERSITIES & COLLEGES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTI-THROMBIN III TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 52. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 53. CANADA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES ANTI-THROMBIN III TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 84. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 85. CHINA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 90. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 91. INDIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 193. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 194. ITALY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 216. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 217. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 218. POLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 219. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 223. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 224. QATAR ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM ANTI-THROMBIN III TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 279. ANTI-THROMBIN III TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 280. ANTI-THROMBIN III TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Anti-Thrombin III Testing Market was valued at USD 91.43 million in 2023, expected to reach USD 99.84 million in 2024, and is projected to grow at a CAGR of 9.39%, to USD 171.37 million by 2030.

Anti-Thrombin III Testing is essential in the medical field as it plays a crucial role in diagnosing and managing thrombotic disorders and ensuring the efficacy of anticoagulant therapies. The necessity of this testing is driven by its application in detecting congenital or acquired deficiencies in Anti-Thrombin III, which can lead to an increased risk of thrombosis. Its applications span across healthcare settings such as hospital laboratories, diagnostic centers, and research institutions, which serve as the primary end-users. Market growth is influenced by rising incidences of thromboembolic disorders, advancements in diagnostic technologies, and an increasing elderly population prone to blood clotting disorders. The growing awareness about coagulation disorders further amplifies the demand. Recently, potential opportunities have arisen from technological advancements that facilitate point-of-care diagnostic tools and the integration of Artificial Intelligence for improved accuracy and efficiency. Companies can capitalize on these opportunities by investing in research partnerships and enhancing their product portfolios with cutting-edge technologies. However, market growth faces challenges such as stringent regulatory requirements, high testing costs, and the need for skilled professionals to conduct and interpret results accurately. These limitations could hinder widespread adoption, particularly in low-income regions. Innovation and research should focus on enhancing non-invasive testing methods, reducing costs, and leveraging digital technologies to ensure easier access and streamlined diagnostics. Emphasizing personalized medicine approaches and developing robust predictive models can open new avenues for business growth. The market is inherently collaborative, where partnerships with hospitals, diagnostic service providers, and academic research bodies could propel innovation. Overall, the Anti-Thrombin III Testing market presents a dynamic landscape where the amalgamation of technological innovation and strategic market engagements can offer substantial growth opportunities despite existing challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Thrombin III Testing Market

The Anti-Thrombin III Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of surgical procedures requiring anti-thrombin III monitoring for better perioperative care
  • Increase in geriatric population prone to thrombotic disorders necessitating regular anti-thrombin III testing
  • Expansion of healthcare infrastructure in emerging economies
• Market Restraints
  • Limited availability of skilled professionals and specialized laboratories for anti-thrombin III testing
• Market Opportunities
  • Expansion of anti-thrombin III testing services in specialized cardiovascular care facilities
  • Collaborations with biotechnology firms to innovate new anti-thrombin III testing methodologies
• Market Challenges
  • Regulatory compliance and stringent guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Thrombin III Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Thrombin III Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Thrombin III Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Thrombin III Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Thrombin III Testing Market

A detailed market share analysis in the Anti-Thrombin III Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Thrombin III Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Thrombin III Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Thrombin III Testing Market

A strategic analysis of the Anti-Thrombin III Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Thrombin III Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories, bioMerieux, Chrono-log Corporation, Danaher Corporation, DiaSorin, Grifols, Immucor, Instrumentation Laboratory, Merck KGaA, PerkinElmer, Quidel Corporation, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, and Werfen.

Market Segmentation & Coverage

This research report categorizes the Anti-Thrombin III Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Cardiac Test Kits, ELISA Test Kits, and FIA Test Kits.
• Based on Technology, market is studied across Chromogenic Assay and Immunoassay.
• Based on Application, market is studied across Diagnostic Laboratories, Point of Care Testing, and Research and Academic Institutes. The Diagnostic Laboratories is further studied across Hospital Laboratories and Independent Diagnostics Laboratories. The Research and Academic Institutes is further studied across Clinical Research Units and Universities & Colleges.
• Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of surgical procedures requiring anti-thrombin III monitoring for better perioperative care
    • 5.1.1.2. Increase in geriatric population prone to thrombotic disorders necessitating regular anti-thrombin III testing
    • 5.1.1.3. Expansion of healthcare infrastructure in emerging economies
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of skilled professionals and specialized laboratories for anti-thrombin III testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion of anti-thrombin III testing services in specialized cardiovascular care facilities
    • 5.1.3.2. Collaborations with biotechnology firms to innovate new anti-thrombin III testing methodologies
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory compliance and stringent guidelines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Thrombin III Testing Market, by Product Type

• 6.1. Introduction
• 6.2. Cardiac Test Kits
• 6.3. ELISA Test Kits
• 6.4. FIA Test Kits

7. Anti-Thrombin III Testing Market, by Technology

• 7.1. Introduction
• 7.2. Chromogenic Assay
• 7.3. Immunoassay

8. Anti-Thrombin III Testing Market, by Application

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
  • 8.2.1. Hospital Laboratories
  • 8.2.2. Independent Diagnostics Laboratories
• 8.3. Point of Care Testing
• 8.4. Research and Academic Institutes
  • 8.4.1. Clinical Research Units
  • 8.4.2. Universities & Colleges

9. Anti-Thrombin III Testing Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals
• 9.5. Specialty Clinics

10. Americas Anti-Thrombin III Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Anti-Thrombin III Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Thrombin III Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories
• 5. bioMerieux
• 6. Chrono-log Corporation
• 7. Danaher Corporation
• 8. DiaSorin
• 9. Grifols
• 10. Immucor
• 11. Instrumentation Laboratory
• 12. Merck KGaA
• 13. PerkinElmer
• 14. Quidel Corporation
• 15. Roche Diagnostics
• 16. Sekisui Diagnostics
• 17. Siemens Healthineers
• 18. Sysmex Corporation
• 19. Thermo Fisher Scientific
• 20. Werfen